AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ORTHOCELL LTD

1.175

-0.120-9.27%

Volume:3.06M

Turnover:3.68M

Market Cap:284.32M

PE:-73.72

High:1.275

Open:1.275

Low:1.160

Close:1.295

Loading ...

Overview Company News Filings

Orthocell's Distributor Starts Selling Collagen Membrane Device in Europe

MT Newswires Live

David Sacks: FDIC Removes 'Reputational Risk,' a Major Victory for Cryptocurrency

Trump's nominated SEC Chairman pick, Paul Atkins, will undergo a Senate hearing next week

ASX Market Close: Index pares gains, Gold hits new record | March 18, 2025

The Market Herald

Orthocell receives regulatory approval for sales of Striate+ dental membrane into Singapore

Why Clarity, New Hope, Orthocell, and West African shares are charging higher today

BRIEF-Regulatory Approval To Commence Striate Sales In Singapore

Up 290% in 12 months: Why this ASX healthcare stock is surging again today

BUZZ-Australia's Orthocell surges on sales approval in Singapore

Orthocell Receives Regulatory Approval for Bone Regeneration Product in Singapore; Shares Up 9%

MT Newswires Live

ASX Alert-Regulatory Approval to Commence Striate Sales in Singapore-Occ.ax

THOMSON REUTERS

Orthocell shares up 10% today; anticipates FDA approval in the coming weeks

Here's Why We're Not Too Worried About Orthocell's (ASX:OCC) Cash Burn Situation

Simply Wall St.

Transportation costs the biggest hurdle in interprovincial trade: survey

Investors bid Orthocell (ASX:OCC) up AU$53m despite increasing losses YoY, taking one-year return to 347%

Simply Wall St.

Orthocell Submits Canada License Application for Nerve Repair Product

MT Newswires Live

BRIEF-Orthocell Submits Canada Regulatory Application To Commence Sales Of Remplir

Orthocell Ltd - Submits Canada Regulatory Application to Commence Sales of Remplir

THOMSON REUTERS

BUZZ-Australia's Orthocell climbs to 2-week high as co floats expansion plans

BRIEF-Orthocell Says Market Expansion Of Remplir Will Be Accelerated

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/OCC.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OCC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OCC.AU\",,,,,undefined,":{"symbol":"OCC.AU","market":"AU","secType":"STK","nameCN":"ORTHOCELL LTD","latestPrice":1.175,"timestamp":1745302320000,"preClose":1.295,"halted":0,"volume":3063650,"delay":0,"nameEN":"ORTHOCELL LTD","floatShares":191252770,"shares":241976241,"eps":-0.015939,"marketStatus":"Not Yet Opened","change":-0.12,"latestTime":"04-22 16:12:00 AEST","open":1.275,"high":1.275,"low":1.16,"amount":3684671,"amplitude":0.088803,"askPrice":1.18,"askSize":10000,"bidPrice":1.17,"bidSize":12077,"shortable":3,"etf":0,"ttmEps":-0.015939,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745366400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":1.295,"openAndCloseTimeList":[[1745280000000,1745301600000]],"volumeRatio":2.402232,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OCC.AU\",,,,,undefined,":{"symbol":"OCC.AU","floatShares":191252770,"roa":"-20.32%","roe":"-29.77%","lyrEps":-0.035547,"volumeRatio":2.4022315706792168,"shares":241976241,"dividePrice":0,"high":1.275,"amplitude":0.088803,"preClose":1.295,"low":1.16,"week52Low":0.35,"pbRate":"14.48","psRate":"45.02","week52High":1.79,"institutionHeld":0,"latestPrice":1.175,"committee":0.09408,"eps":-0.015939,"divideRate":0,"volume":3063650,"delay":0,"ttmEps":-0.015939,"open":1.275,"prevYearClose":1.355,"prevWeekClose":1.295,"prevMonthClose":1.495,"prevQuarterClose":1.495,"fiveDayClose":1.42,"twentyDayClose":1.47,"sixtyDayClose":1.615},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OCC.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522379038","title":"Orthocell's Distributor Starts Selling Collagen Membrane Device in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2522379038","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522379038?lang=en_us&edition=fundamental","pubTime":"2025-03-26 07:28","pubTimestamp":1742945297,"startTime":"0","endTime":"0","summary":"Orthocell  said its distributor unit BioHorizons Camlog, has completed the first sale and is now actively selling the company's collagen membrane device used for guided bone and tissue regeneration in dental applications Striate+, in Germany, Austria, and Switzerland, according to a Wednesday filing with the Australian bourse.Regulatory approval for the Striate+ in Brazil is anticipated within the next three months, with additional applications currently under review, the filing said.Price : $1.50, Change: $-0.060, Percent Change: -3.85%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OCC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2522004813","title":"David Sacks: FDIC Removes 'Reputational Risk,' a Major Victory for Cryptocurrency","url":"https://stock-news.laohu8.com/highlight/detail?id=2522004813","media":"Blockbeats","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522004813?lang=en_us&edition=fundamental","pubTime":"2025-03-25 23:31","pubTimestamp":1742916660,"startTime":"0","endTime":"0","summary":"BlockBeats News, March 25th, David Sacks, the U.S. cryptocurrency and AI chief, stated that the Federal Deposit Insurance Corporation  is following in the footsteps of the Office of the Comptroller of the Currency  by eliminating \"reputational risk\" as a factor in bank regulation, calling it a great victory for cryptocurrency.\"Reputational risk\" sounds good in theory, but its definition is \"the risk that negative publicity regarding a financial institution's business practices, whether true or not, will lead to a reduced customer base, expensive litigation, or reduced revenue potential.\" In practice, this vague and subjective standard has been used to justify the denial of banking services to legitimate cryptocurrency businesses through \"Operation Choke Point 2.0.\" Banking standards should be objective and quantifiable, rather than based on potentially untrue narratives.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/286965","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["US5Y.BOND","US10Y.BOND","US12M.BOND","US6M.BOND","BK7508","BK4020","OCC","US7Y.BOND","US2Y.BOND","OCC.AU","US3Y.BOND","US30Y.BOND","BK7067"],"gpt_icon":0},{"id":"2521490029","title":"Trump's nominated SEC Chairman pick, Paul Atkins, will undergo a Senate hearing next week","url":"https://stock-news.laohu8.com/highlight/detail?id=2521490029","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521490029?lang=en_us&edition=fundamental","pubTime":"2025-03-21 06:24","pubTimestamp":1742509440,"startTime":"0","endTime":"0","summary":"BlockBeats News, March 21st, Paul Atkins, the nominee for Chair of the U.S. Securities and Exchange Commission , will attend a confirmation hearing at the Senate Banking Committee on March 27th. If confirmed, the full Senate will proceed with a final vote. Atkins, a former SEC commissioner, is a supporter of digital assets and previously founded a financial compliance consulting firm in Washington. He is expected to continue the pro-crypto regulatory stance pushed by the Trump administration, succeeding former SEC Chair Gary Gensler, who faced criticism for his \"enforcement-heavy\" approach to the crypto industry.The same-day hearing will also include Jonathan Gould, the nominee for Comptroller of the Currency , the agency responsible for regulating U.S. national banks, which is crucial for crypto companies seeking bank access and stablecoin issuance regulation. Additionally, the Senate will also consider the nomination of Luke Pettit as Assistant Secretary of the Treasury.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/286446","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["TON.USD.CC","BK4020","BK7067","SEC.AU","OCC.AU","US12M.BOND","WASH","APT.USD.CC","APT.USD.HKCC","US10Y.BOND","TON.USD.HKCC","US3Y.BOND","US30Y.BOND","OCC","US5Y.BOND","US7Y.BOND","US6M.BOND","BK4211","US2Y.BOND","BK7508"],"gpt_icon":0},{"id":"2520469206","title":"ASX Market Close: Index pares gains, Gold hits new record | March 18, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520469206","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520469206?lang=en_us&edition=fundamental","pubTime":"2025-03-18 14:01","pubTimestamp":1742277660,"startTime":"0","endTime":"0","summary":"The ASX200 pared early gains to close up by a sliver of less than a tenth of a percent at 7860 points.Utilities was the best performing sector, up 1.7%, followed by Real Estate, up 0.7%, and Energy, up 0.6%.Discretionay was the worst performing sector, down 0.6%, followed by Financials, down around 0.2%.Orthocell  closed up 5.5% after Singapore’s Health Sciences Authority granted regulatory approval for its market leading dental membrane, Striate+.New Hope  finished the day up 8.9% after itshalf year results revealed a 22% increase in underlying EBITDA, to $517 million, and a 35% jump in net profit after tax to $340 million. The company declared a fully franked interim dividend of 19 cents per share.West African Resources  closed up 3.6% on an update on its Sanbrado gold production centre in Burkina Faso. The company has achieved positive results and there is potential for an underground development beneath the Toega open pit mine.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-index-pares-gains-gold-hits-new-record-march18-2025-2025-03-18/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7503","APX.AU","BK7506","BK7067","BK7104","ARI.AU","OCC.AU","WAF.AU","BK7508","EDV.AU","BK7040","BK7061","BK7083","BK7095","NHC.AU"],"gpt_icon":0},{"id":"2520652464","title":"Orthocell receives regulatory approval for sales of Striate+ dental membrane into Singapore","url":"https://stock-news.laohu8.com/highlight/detail?id=2520652464","media":"Small Caps","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520652464?lang=en_us&edition=fundamental","pubTime":"2025-03-18 11:05","pubTimestamp":1742267154,"startTime":"0","endTime":"0","summary":"Orthocell  has received regulatory approval from Singapore’s Health Sciences Authority to commence regional sales of its dental membrane product Striate+ for use in guided bone and tissue regeneration applications.The company said its Striate+ global marketing and distribution partner BioHorizons was already established in the Singapore market and would facilitate a fast transition to first sales and revenue generation.Orthocell considers Singapore a key regulatory hub and a stepping stone to approvals in other Asian markets.Orthocell chief executive officer Paul Anderson said the company was pleased to have received approval to sell Striate+ in an important regional market.“This approval provides additional validation of our high-quality products, manufacturing processes and quality systems,” he said.“The product’s unique features — such as its ease of use, ability to conform to treatment surfaces and promotion of more efficient bone growth — have driven high adoption and contributed ","market":"hk","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/03/Orthocell-ASX-OCC-Striate-Singapore.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/03/Orthocell-ASX-OCC-Striate-Singapore.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/orthocell-regulatory-approval-sales-striate-dental-membrane-singapore/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK7067","OCC.AU","BK7508"],"gpt_icon":0},{"id":"2520516496","title":"Why Clarity, New Hope, Orthocell, and West African shares are charging higher today","url":"https://stock-news.laohu8.com/highlight/detail?id=2520516496","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520516496?lang=en_us&edition=fundamental","pubTime":"2025-03-18 10:11","pubTimestamp":1742263881,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) is on form again and pushing higher on Tuesday. In afternoon trade, the benchmark index is up 0.2% to 7,870.2 points. Four ASX shares that are rising more than most tod","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/18/why-clarity-new-hope-orthocell-and-west-african-shares-are-charging-higher-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7508","XJO.AU","BK7506","BK7083","BK7067","HOPE","OCC.AU","BK4211","NHC.AU","WAF.AU","BK7104","BK7096","CU6.AU"],"gpt_icon":0},{"id":"2520631459","title":"BRIEF-Regulatory Approval To Commence Striate Sales In Singapore","url":"https://stock-news.laohu8.com/highlight/detail?id=2520631459","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520631459?lang=en_us&edition=fundamental","pubTime":"2025-03-18 08:53","pubTimestamp":1742259196,"startTime":"0","endTime":"0","summary":"BRIEF-Regulatory Approval To Commence Striate Sales In SingaporeMarch 18 (Reuters) - Orthocell Ltd OCC.AX:ASX ALERT-REGULATORY APPROVAL TO COMMENCE STRIATE SALES IN SINGAPORE-OCC.AXFurther company coverage: OCC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nFWN3Q00UI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCC.AU"],"gpt_icon":0},{"id":"2520632696","title":"Up 290% in 12 months: Why this ASX healthcare stock is surging again today","url":"https://stock-news.laohu8.com/highlight/detail?id=2520632696","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520632696?lang=en_us&edition=fundamental","pubTime":"2025-03-18 08:24","pubTimestamp":1742257472,"startTime":"0","endTime":"0","summary":"Orthocell Ltd  shares are catching the eye again on Tuesday.In morning trade, the ASX healthcare stock is up 11% to $1.53.This means that the regenerative medicine company's shares are now up 290% since this time last year.To put that into context, a $5,000 investment 12 months ago would now be worth almost $20,000 today.Investors have been buying the company's shares this morning after it made another big announcement.According to the release, Singapore's Health Sciences Authority  has granted regulatory approval for its market leading dental membrane, Striate+. This is for use in guided bone and tissue regeneration applications.Commenting on the news, the ASX healthcare stock's CEO and managing director, Paul Anderson, said:. We are delighted to receive Singaporean regulatory approval for Striate+ in this important regional gateway market. This approval provides additional validation of Orthocell's high-quality products, manufacturing processes, and quality systems. Moreover, it enha","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/18/up-290-in-12-months-why-this-asx-healthcare-stock-is-surging-again-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7508","BK7067","OCC.AU"],"gpt_icon":0},{"id":"2520163685","title":"BUZZ-Australia's Orthocell surges on sales approval in Singapore","url":"https://stock-news.laohu8.com/highlight/detail?id=2520163685","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520163685?lang=en_us&edition=fundamental","pubTime":"2025-03-18 08:14","pubTimestamp":1742256883,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Orthocell surges on sales approval in Singapore** Shares of Orthocell OCC.AX rise 11% to A$1.52, hitting their highest levels since Feb 20** The biotech firm receives regulatory approval from Singapore's Health Sciences authority to start sales of its Striate+ product** Striate+ is a dental guided bone regeneration product** Says co working with Striate+ distribution partner BioHorizons to fast-track expansion to other regions including Brazil** Stock up ~11.1% YTD, including current session's moves  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nL4N3Q1009:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCC.AU"],"gpt_icon":0},{"id":"2520776635","title":"Orthocell Receives Regulatory Approval for Bone Regeneration Product in Singapore; Shares Up 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2520776635","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520776635?lang=en_us&edition=fundamental","pubTime":"2025-03-18 08:09","pubTimestamp":1742256559,"startTime":"0","endTime":"0","summary":"Orthocell  received regulatory approval from Singapore's Health Sciences Authority to market and sell its Striate+ dental membrane for guided bone and tissue regeneration applications in the country, according to a Tuesday filing with the Australian bourse.The company is on track to receive regulatory clearance for Striate+ in Brazil within three to six months, the filing said.Shares were up 9% in morning trade Tuesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","OCC.AU","BK7508"],"gpt_icon":0},{"id":"2520680107","title":"ASX Alert-Regulatory Approval to Commence Striate Sales in Singapore-Occ.ax","url":"https://stock-news.laohu8.com/highlight/detail?id=2520680107","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520680107?lang=en_us&edition=fundamental","pubTime":"2025-03-18 06:59","pubTimestamp":1742252367,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nFWN3Q00UI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OCC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2520302597","title":"Orthocell shares up 10% today; anticipates FDA approval in the coming weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2520302597","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520302597?lang=en_us&edition=fundamental","pubTime":"2025-03-17 13:11","pubTimestamp":1742188303,"startTime":"0","endTime":"0","summary":"Orthocell Ltd  share price is catching the eye of investors on Monday. In late afternoon trade, the regenerative medicine company's shares are up over 10% to $1.37. This means that Orthocell shares are now up approximately 250% since this time last year. What is Orthocell?Also potentially giving the Orthocell share price a boost is its addition in the All Ordinaries index. The company will be officially added to the index next Monday following the quarterly rebalance This could have opened up the company to fund managers that have strict investment mandates preventing them from investing in companies outside the index. It could also mean that funds tracking the index are buying shares ahead of its inclusion.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/17/orthocell-shares-up-10-today-anticipates-fda-approval-in-the-coming-weeks/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["XAO.AU","BK7067","XKO.AU","BK7508","XJO.AU","OCC.AU"],"gpt_icon":0},{"id":"2514041834","title":"Here's Why We're Not Too Worried About Orthocell's (ASX:OCC) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2514041834","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514041834?lang=en_us&edition=fundamental","pubTime":"2025-02-26 04:36","pubTimestamp":1740515815,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Orthocell  has seen its share price rise 196% over the last year, delighting many shareholders. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.So notwithstanding the buoyant share price, we think it's well worth asking whether Orthocell's cash burn is too risky. In this article, we define cash burn as its annual  free cash flow, which is the amount of money a company spends each year to fund its growth. First, we'll determine its cash runway by comparing its cash burn with its cash reserves.As you can probably tell by now, we're not too worried about Orthocell's cash burn. For example, we think its cash runway suggests that the company is on a good path. While its increasing cash burn wasn't great, the other factors mentioned in this article more than make up for","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-were-not-too-203655065.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["OCC.AU","BK4020","OCC","BK7067","BK7508"],"gpt_icon":0},{"id":"2512092594","title":"Transportation costs the biggest hurdle in interprovincial trade: survey","url":"https://stock-news.laohu8.com/highlight/detail?id=2512092594","media":"Bloomberg","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512092594?lang=en_us&edition=fundamental","pubTime":"2025-02-16 07:12","pubTimestamp":1739661145,"startTime":"0","endTime":"0","summary":"A national survey suggests transportation costs are the most common hindrance to interprovincial trade for businesses both selling and purchasing goods and services.","market":"hk","thumbnail":"https://cloudfront-us-east-1.images.arcpublishing.com/bellmediainc/WYKGOL7R5BC47JMLLWP4ERAP7A.jpg","type":0,"news_type":0,"thumbnails":["https://cloudfront-us-east-1.images.arcpublishing.com/bellmediainc/WYKGOL7R5BC47JMLLWP4ERAP7A.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bnnbloomberg.ca/business/politics/2025/02/15/transportation-costs-the-biggest-hurdle-in-interprovincial-trade-survey/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bnn_bloomberg_highlight","symbols":["BK7508","BK7067","OCC","OCC.AU","BK4020"],"gpt_icon":0},{"id":"2509734013","title":"Investors bid Orthocell (ASX:OCC) up AU$53m despite increasing losses YoY, taking one-year return to 347%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509734013","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509734013?lang=en_us&edition=fundamental","pubTime":"2025-02-07 04:00","pubTimestamp":1738872045,"startTime":"0","endTime":"0","summary":"For many, the main point of investing in the stock market is to achieve spectacular returns. While not every stock...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-occ/orthocell-shares/news/investors-bid-orthocell-asxocc-up-au53m-despite-increasing-l","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ISBC","BK4211","BK7508","OCC.AU","BK4020","OCC","BK7067"],"gpt_icon":0},{"id":"2508154166","title":"Orthocell Submits Canada License Application for Nerve Repair Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2508154166","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508154166?lang=en_us&edition=fundamental","pubTime":"2025-02-03 07:46","pubTimestamp":1738539985,"startTime":"0","endTime":"0","summary":"Orthocell  submitted a medical device license application in Canada for its nerve repair product Remplir, according to a Monday Australian bourse filing.The company expects the product to be approved in Canada in the second half of 2025.It is planning to submit regulatory applications in Thailand in the March quarter, in the UK and the European Union in the September quarter, and in Brazil in the December quarter.It is also evaluating Southeast Asian and Latin American markets.It added that it expects US Food and Drug Administration approval in March or early April. Preparations for a market launch in the US are underway.The company's shares fell past 3% in recent Monday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","OCC.AU","BK7067"],"gpt_icon":0},{"id":"2508159463","title":"BRIEF-Orthocell Submits Canada Regulatory Application To Commence Sales Of Remplir","url":"https://stock-news.laohu8.com/highlight/detail?id=2508159463","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508159463?lang=en_us&edition=fundamental","pubTime":"2025-02-03 06:33","pubTimestamp":1738535597,"startTime":"0","endTime":"0","summary":"BRIEF-Orthocell Submits Canada Regulatory Application To Commence Sales Of RemplirFeb 3 (Reuters) - Orthocell Ltd OCC.AX:SUBMITS CANADA REGULATORY APPLICATION TO COMMENCE SALES OF REMPLIRFurther company coverage: OCC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250202:nFWN3OS06F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCC.AU"],"gpt_icon":0},{"id":"2508315673","title":"Orthocell Ltd - Submits Canada Regulatory Application to Commence Sales of Remplir","url":"https://stock-news.laohu8.com/highlight/detail?id=2508315673","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508315673?lang=en_us&edition=fundamental","pubTime":"2025-02-03 06:01","pubTimestamp":1738533685,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250202:nFWN3OS06F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OCC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2505766845","title":"BUZZ-Australia's Orthocell climbs to 2-week high as co floats expansion plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2505766845","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505766845?lang=en_us&edition=fundamental","pubTime":"2025-01-22 12:49","pubTimestamp":1737521354,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Orthocell climbs to 2-week high as co floats expansion plans** Shares of Orthocell OCC.AX rise 15.4% to A$1.500, their highest levels since Jan 6** The regenerative medicine firm says that it plans to enter key markets such as Canada and Thailand, among others, in CY2025** Orthocell recently submitted its USFDA regulatory application for the clearance to distribute its nerve drug Remplir in the $1.6 bln  U.S. market commercially** Co expects approval in March/April 2025** About 3.4 mln shares trade hands, 1.9 times the 30-day average of 1.8 mln** Stock rose 230.5% in 2024  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nL3N3OI0BN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","OCC.AU","BK7508"],"gpt_icon":0},{"id":"2505753628","title":"BRIEF-Orthocell Says Market Expansion Of Remplir Will Be Accelerated","url":"https://stock-news.laohu8.com/highlight/detail?id=2505753628","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505753628?lang=en_us&edition=fundamental","pubTime":"2025-01-22 09:31","pubTimestamp":1737509461,"startTime":"0","endTime":"0","summary":"BRIEF-Orthocell Says Market Expansion Of Remplir Will Be AcceleratedJan 22 (Reuters) - Orthocell Ltd OCC.AX:MARKET EXPANSION OF REMPLIR WILL BE ACCELERATED AHEAD OF US FDA CLEARANCE EXPECTED IN MARCH/","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nFWN3OH1XT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCC.AU","BK7508","BK7067"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":70,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OCC.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OCC.AU\",market:\"AU\",,,undefined,":[]}}